Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study
Abstract
BACKGROUND: Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist. However, robust evidence about its efficacy and safety in primary aldosteronism is scarce. METHODS: In this prospective, multicenter, single-arm, and exploratory trial, we enrolled adults (aged ≤75 years) with primary aldosteronism, an office blood pressure (BP) ranging from 140 to 180/90 to 120 mm Hg, and an estimated glomerular filtration rate ≥60 mL/min per 1.73 m². Eligible patients received finerenone (20–40 mg/d) treatment for 12 weeks. The primary outcome was the change in daytime systolic BP at 12 weeks. RESULTS: Fifty-seven patients were ultimately treated. Per-protocol analysis revealed that finerenone treatment significantly reduced mean daytime systolic BP (−6.69±1.60 mm Hg; P
Fields of Study & Subjects
Hormonal Regulation and Hypertension
Renin-Angiotensin System Studies
Adrenal Hormones and Disorders
Publication details
- Journal / source
- Hypertension
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 83
- Issue
- 5
- Pages
- e26048–e26048
- Publication date
- 22 January 2026
- Language
- EN